FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - June 27, 2025 401 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARANOTE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ΠΩΣ ΠΡΟΚΑΛΕΙΤΑΙ January 18, 2019 Beloved Kansas City Jazz Singer Passes Away at 48 After 13-Year... December 3, 2020 New Research in Treating Leukemia and Lymphoma: ASH Annual Meeting 2020 January 15, 2021 EMA Recommends Granting a Marketing Authorisation for a Biosimilar Bevacizumab, Onbevzi November 23, 2020 Load more HOT NEWS Tucatinib Added to Trastuzumab and Capecitabine Continues to Demonstrate a Significant... French Senate Committee Backs ESMO Call to Revise EU Regulation to... Selpercatinib Slows Progression of RET-Positive Lung, Medullary Thyroid Cancers The IGCCCG Update Model Allows Improved and More Granular Individual Prognostic...
